Alpha Healthcare Acquisition Corp. III (NASDAQ:ALPA) announced this afternoon that its shareholders approved its combination with drug developer Carmell at a special meeting held on July 11.
At yesterday’s meeting, a total of at least 15,511,079 shares, or 78.46%, of ALPA’s issued and outstanding common stock were present either in person or by proxy, which constituted a quorum.
Redemption figures and a closing timeline have not been disclosed by the parties, but the deal received support from investors holding a total of 12,006,101 shares that voted in favor of it.
Earlier this week, Alpha Healthcare III signed a forward purchase agreement (FPA) and a non-redemption agreement to support its combination with Carmell. As part of the agreement, Meteora Special Opportunity Fund I will purchase an amount of shares equal to 9.5% of ordinary Alpha Healthcare III stock at close. It will be prepaid for these purchases at its redemption price out of funds from the SPAC’s trust.
Additionally, Meteora agreed to not redeem 100,000 other shares that it currently holds.
Alpha Healthcare III initially inked the $188 million merger with Carmell in January. Pittsburgh-based Carmell is developing a treatment platform to accelerate healing in bone fractures and soft tissue wounds.
The combined company is expected to trade on the Nasdaq under the symbol “CTCX” once the deal is completed.
FG Merger III Corp. filed for a $150 million IPO yesterday afternoon, marking the third SPAC to file on Wednesday. Similar to Blue Room (NASDAQ:IBLUU), which filed its $200 million IPO yesterday morning, FG Merger III intends to focus its search for a target business in the financial services industry in North America. Notably, FG...
10X Capital Venture Acquisition Corp. II (NASDAQ:VCXA) announced that it has completed its business combination with African Agriculture after shareholders approved the deal at a special meeting held on December 5. In connection with the meeting, 10X II received redemption requests for 1,857,033 Class A ordinary shares, representing 98.7% in aggregate redemptions since 10X II’s...
At the SPAC of Dawn The latter half of 2023 has largely told a story of retrenchment in the SPAC market as much of the excess in the domain has found itself terminating and liquidating. But, the increase in outgoing has not completely canceled out the boom in incoming as three new SPACs filed to...
TechyBird Acquisition Corp. (NASDAQ:TKBD) filed for a $60 million IPO today, putting it in line to become the second 2023 IPO from an underwriter that is relatively new to the SPAC space. That underwriter, Spartan Capital Securities, brought Aimei Health Technology (NASDAQ:AFJK) to market last week with similar terms as this new member to its...
Blue Room Acquisition Corp. (NASDAQ:IBLUU) submitted its S-1 filing this morning for a $200 million IPO. The new SPAC has set its sights on targets in the financial sector, ranging in market value between $250 million and $500 million, and primarily situated in the U.S. Its primary objective is to identify an innovative company leveraging...